TFFP - TFF Pharmaceuticals and NeuroRX in feasibility collaboration

NeuroRx and TFF Pharmaceuticals ([[TFFP]] +8.2%) are announcing that the companies have entered into a feasibility and material transfer agreement.Under the agreement, NeuroRx is delivering ZYESAMI™ materials to TFF in order to perform feasibility formulation work and testing.The dry powder inhalation technology has the potential to deliver ZYESAMI directly to the lungs."We are excited that ZYESAMI has demonstrated a highly significant reduction in time to hospital discharge for seriously ill Covid-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety," said Jonathan C. Javitt, M.D., M.P.H., CEO of NeuroRx.

For further details see:

TFF Pharmaceuticals and NeuroRX in feasibility collaboration